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OBJECTIVES Our aim was to examine the relationships between serum hematocrit (Hct) and risk of
all-cause mortality among patients with severe heart failure (HF).
BACKGROUND Anemia occurs with increased frequency in severe HF. However, few studies have examined
the impact of anemia on mortality in this population.
METHODS Using a prospective cohort design, we evaluated the relationships between baseline serum Hct
and mortality among 1,130 patients with left ventricular EF 30% and New York Heart
Association functional class IIIB or IV HF treated with angiotensin-converting enzyme
inhibitors, diuretics, and digitalis. Mortality was ascertained by centralized adjudication.
RESULTS The mean Hct was 41.8% (range 25.4% to 58.8%). Over 15 months of mean follow-up, there
were 407 deaths (29 per 100 person-years). After adjustment for potential confounders, those
in the lowest quintile of Hct (range 25.4% to 37.5%) had a 52% higher risk of death (hazard
ratio 1.52, 95% confidence interval 1.11 to 2.10), compared with the highest quintile (range
46.1% to 58.8%). Within the lowest quintile of Hct, each 1% decrease in Hct was associated
with an 11% higher risk of death (p 0.01), whereas within the four higher quintiles of Hct,
Hct was not associated with total mortality. Evaluation of different causes of death indicated
that a lower Hct was strongly associated with death from progressive HF, rather than sudden
death or other deaths.
CONCLUSIONS Among patients with severe HF, anemia is a significant independent risk factor for death,
with a progressively higher risk with increasing severity of anemia. Further investigation of
the etiologies, prevention, and treatment of anemia in severe HF is warranted. (J Am Coll
Cardiol 2003;41:1933–9) © 2003 by the American College of Cardiology Foundation
While mortality from coronary artery disease and stroke has
been declining, the incidence and health burden of conges-
tive heart failure (HF) continue to rise (1). In the U.S.,
nearly 5 million people have HF and more than half a
million new cases are diagnosed each year; HF is the most
common cause of hospitalization among persons age 65
years; and health care costs for HF exceed $20 billion
annually (1,2). Despite advances in medical treatment, HF
patients have high mortality rates, and HF deaths have
increased 145% over the last two decades (1). People with
severely reduced left ventricular systolic function and severe
HF symptoms are at particular risk, with mortality rates
approaching 30% per year. These trends, mirrored in other
industrialized nations (3–5), accentuate the importance of
identifying and treating novel risk factors for poor outcomes
in HF.
Accumulating evidence suggests that anemia may be an
independent risk factor for mortality among patients with
HF (6–9). Additionally, clinical studies among small num-
bers of HF patients (n  26 [10] and n  32 [11]) indicate
that treatment of anemia with erythropoietin and iron
improves symptoms and the ejection fraction (EF) and
decreases hospitalizations and the need for diuretics, sug-
gesting that anemia may be a modifiable risk factor in HF
with a causal role in clinical outcomes. However, few
previous studies have characterized the impact of anemia on
HF mortality, such as the magnitude of risk, threshold of
risk, or associations with different causes of death, and only
one previous study (9) has examined patients with severe
HF, the population at highest risk for both anemia and
death.
We therefore investigated, using a prospective cohort
design, the relationships between baseline serum hematocrit
(Hct) and mortality among 1,130 subjects enrolled in the
Prospective Randomized Amlodipine Survival Evaluation
(PRAISE), a randomized trial of amlodipine versus placebo
among patients with severe HF. Our primary hypothesis
was that a lower Hct would be associated with a higher risk
of all-cause mortality among these patients with severe HF.
METHODS
Study design and population. We used baseline informa-
tion and follow-up data from PRAISE, a multicenter,
randomized clinical trial of amlodipine versus placebo
among 1,153 men and women with left ventricular EF
30% and New York Heart Association (NYHA) func-
tional class IIIB or IV HF symptoms treated with
angiotensin-converting enzyme inhibitors, diuretics, and
digitalis. Patients with both ischemic and nonischemic HF
were enrolled. The design, inclusion and exclusion criteria,
and primary results have been previously described (12).
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The protocol was approved by the institutional review
boards of all 105 participating institutions, and informed
written consent was obtained from all subjects. Laboratory
analyses, including Hct, were performed at a central labo-
ratory (Hct normal range 41% to 50% in men and 33% to
46% in women). We excluded 23 participants with missing
baseline Hct measurements, resulting in 1,130 participants
included in this analysis.
Ascertainment and classification of mortality. All deaths
were reviewed and classified by a centralized adjudication
committee based on information from hospital and emer-
gency room records, electrocardiograms, chest X-rays, au-
topsy reports, death certificates, and statements from wit-
nesses (12,13). Cardiac deaths were categorized as sudden
death, pump failure death, or fatal myocardial infarction
(MI). Sudden death was defined as death from cardiac or
unknown causes that was unexpected and occurred after an
abrupt loss of consciousness in a previously stable patient.
Pump failure death was defined as progressive HF culmi-
nating in death not due to acute MI or observed or
suspected life-threatening arrhythmia; heart transplanta-
tions (n  8) were included as pump failure deaths. Deaths
60 min from the onset of symptoms for hospitalized acute
MI were classified as fatal MI. The primary outcome of this
analysis was all-cause mortality. We also evaluated different
causes of death, such as pump failure death. No patients
were lost to follow-up.
Statistical analysis. Hematocrit was evaluated as an indi-
cator variable (dummy variable) in quintiles and deciles, and
as a continuous variable. Baseline characteristics were com-
pared across quintiles of Hct using regression, with the
characteristic as the dependent variable and Hct quintile as
the independent variable. Kaplan-Meier estimates were
used to evaluate survival over time, with differences evalu-
ated using the log-rank test for equality of survivor func-
tions. Cox proportional hazards models were used to eval-
uate risk, with multivariate Cox models evaluated to assess
for confounders. Age, gender, HF etiology, and NYHA
functional class were included in an initial multivariate Cox
model. Other characteristics were added, both individually
and in groups, and retained in the final model based on
clinical interest or an appreciable change (5%) in the
hazard ratio (HR) associated with Hct. In addition to the
characteristics in the final model (age, gender, diabetes,
smoking, HF etiology, EF, NYHA functional class, systolic
blood pressure, white blood cell count, and creatinine), we
also evaluated for potential confounding by race, heart rate,
diastolic blood pressure, cardiothoracic ratio, furosemide use
and dose, metolazone use and dose, potassium-sparing
diuretic use, treatment assignment (amlodipine or placebo),
allopurinol use, uric acid, serum cholesterol, triglycerides,
estimated creatinine clearance, blood urea nitrogen, sodium,
and lymphocyte count. Likelihood ratio testing was used to
assess for the effect modification by age, gender, diabetes,
smoking, NYHA functional class, and etiology of HF. All p
values were two-tailed. Analyses were performed using Stata
version 6.0 (Stata Corp., College Station, Texas).
RESULTS
Baseline characteristics overall and according to quintiles of
Hct are presented in Table 1. The mean Hct was 41.8%
(range 25.4% to 58.8%). The average age of the participants
was 65 years at baseline. Three-quarters of participants were
male, and more than one-third were diabetic. The mean EF
was 21%, with 81% of participants with NYHA functional
class IIIB and 19% with class IV symptoms. A higher Hct
value was associated with younger age, male gender, more
prevalent smoking, slightly lower EF, and higher blood
pressure. Hematocrit was also positively associated with the
white blood cell count, mean corpuscular volume, indexes of
liver function, and serum cholesterol and inversely associ-
ated with blood urea nitrogen and creatinine.
Over 15 months of mean follow-up, there were 407
deaths (29 deaths per 100 person-years). Cardiac deaths
accounted for the vast majority (87%) of fatalities, including
182 sudden deaths, 162 pump failure deaths, and 12 fatal
MIs. In Kaplan-Meier survival analyses, those in the lowest
quintile of Hct had significantly poorer survival, whereas
survival in the four higher quintiles was relatively similar
(Fig. 1). After adjustment for age, gender, diabetes, smok-
ing, HF etiology, EF, NYHA functional class, systolic
blood pressure, white blood cell count, and creatinine, those
in the lowest quintile of Hct (range 25.4% to 37.5%) had a
52% higher risk of death (HR 1.52, 95% confidence interval
[CI] 1.11 to 2.10), compared with the highest quintile of
Hct (range 46.1% to 58.8%) (Table 2). In contrast, subjects
in the second, third, and fourth quintiles of Hct did not
have significantly different mortality compared with those in
the highest quintile (Table 2). When Hct was evaluated in
deciles, there was significantly higher mortality only in the
lowest decile (Hct 35.4%) and no significant associations
in the second to ninth deciles, compared with the highest
decile (Hct 48.3%) as the reference group (Fig. 2).
There also appeared to be a threshold of risk when Hct
was evaluated continuously. After adjustment for potential
confounders (Table 2, footnote), each 1% decrease in Hct
was associated with a 3% higher risk of death (HR 1.03,
95% CI 1.01 to 1.05, p  0.01) in the overall cohort.
However, this association was entirely due to a higher risk in
Abbreviations and Acronyms
CI  confidence interval
EF  ejection fraction
Hct  hematocrit
HF  heart failure
HR  hazard ratio
MI  myocardial infarction
NYHA  New York Heart Association
PRAISE  Prospective Randomized Amlodipine
Survival Evaluation
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the lowest quintile of Hct (range 25.4% to 37.5%), within
which each 1% decrease in Hct was associated with an 11%
higher risk of death (HR 1.11, 95% CI 1.02 to 1.20, p 
0.01). In contrast, there was no association between each 1%
decrease in Hct and total mortality (HR 1.01, 95% CI 0.98
to 1.04, p  0.58) within the four higher quintiles (Hct
37.5%).
Because women normally have lower Hct values than
men, we also evaluated associations with quintiles of Hct
derived separately for men versus women (Table 3). After
adjustment for potential confounders, both men and women
in the lowest quintile of Hct had an approximately 60%
higher risk of mortality, compared with those in the highest
quintile, although the power was limited to confirm this
finding among women because of fewer numbers of female
participants.
When we evaluated different causes of death, there was a
strong inverse association between Hct and pump failure
death, with a significantly higher risk as Hct decreased
across quintiles (p for trend 0.001) (Table 4, Fig. 3). In
similar analyses with Hct evaluated continuously, each 1%
decrease in Hct was associated with an 8% higher risk of
pump failure death (HR 1.08, 95% CI 1.05 to 1.12, p 
0.001). In contrast, there was a suggestion of a U-shaped
relationship with other causes of death (e.g., sudden death
and other deaths), with trends toward a higher risk among
those in the lowest and highest quintiles of Hct (Table 4,
Fig. 3). We evaluated this possible U-shaped relationship by
adding a squared Hct term to the model: both the term (p
 0.03) and the likelihood ratio test (p  0.04) were
significant. In continuous analyses, the risk of these non-
pump failure deaths was greatest for each 1% decrease in
Hct below 36% (HR 1.18, 95% CI 1.01 to 1.37, p  0.04;
n 138) and each 1% increase in Hct above 47% (HR 1.12,
95% CI 1.00 to 1.26, p  0.06; n  180); there was no
relationship with non-pump failure deaths when Hct was
between 36% and 47% (HR 1.00, 95% CI 0.94 to 1.05, p 
0.88; n  812). Evaluation of sudden deaths and other
deaths separately did not greatly alter these results, although
the CIs were broader due to fewer total events.
There was little evidence that the associations between
Hct and mortality varied according to age, gender, diabetes,
smoking, NYHA functional class, or etiology of HF (p 
0.05 by the likelihood ratio test for each interaction). All
findings were similar if hemoglobin was used instead of Hct.
DISCUSSION
Among these patients with severe HF, we observed a
significant and independent association between anemia and
total mortality, with progressively higher mortality with
increasing severity of anemia. Hematocrit was not associ-
ated with total mortality when values were within or near
normal ranges, suggesting a potential threshold of risk
Table 1. Baseline Characteristics According to Quintiles of Hematocrit and Overall
First
(n  229)
Second
(n  224)
Third
(n  229)
Fourth
(n  223)
Fifth
(n  225)
Overall
(n  1,130)
Hematocrit range (%) 37.6 37.6–40.6 40.7–43.0 43.1–46.0 46.0 25.4–58.8
Hemoglobin (g/dl) 11.6  0.9 13.1  0.5 14.0  0.4 14.8  0.5 16.2  0.9* 13.9  1.7
Age (yrs) 68  10 66  10 65  11 64  12 62  12* 65  11
Male (%) 67 63 77 83 90* 76
White race (%) 74 77 77 80 75 77
Diabetes (%) 42 35 32 40 35 37
Current smoking (%) 10 15 15 14 27* 16
Ejection fraction (%) 21  6 21  6 21  6 21  6 20  6† 21  6
NYHA functional class IV (%) 23 21 15 18 21 20
Ischemic etiology (%) 66 62 66 66 60 64
Systolic BP (mm Hg) 115  18 117  19 119  18 119  18 118  17† 118  18
Diastolic BP (mm Hg) 68  12 71  10 72  9 75  10 76  10* 72  11
Heart rate (beats/min) 81  13 80  13 77  13 80  13 82  13 80  13
Furosemide (%) 96 97 97 97 97 97
Furosemide (mg/day) 100  78 97  74 90  71 91  69 102  80 96  74
Metolazone (%) 22 22 17 22 20 21
K-sparing diuretic (%) 3.5 3.1 1.7 2.7 1.3 2.5
Creatinine (mg/dl) 1.5  0.6 1.3  0.4 1.3  0.5 1.4  0.5 1.3  0.4‡ 1.4  0.5
Creatinine 1.5 mg/dl (%) 38 24 18 23 18* 25
Blood urea nitrogen (mg/dl) 32  19 26  14 23  12 26  15 24  12* 26  15
Sodium (mEq/l) 139  4 139  4 139  4 140  4 139  4 139  4
White blood cells (1,000/l) 7.6  3 7.4  2 7.4  2 7.7  2 8.4  2* 7.7  2
MCV (m3) 87  7 89  6 90  6 90  6 91  7* 90
Total bilirubin (mg/dl) 0.7  0.6 0.7  0.5 0.8  0.6 0.8  0.5 1.0  0.6* 0.8
Albumin (g/dl) 3.9  0.4 4.1  0.3 4.2  0.4 4.2  0.4 4.2  0.3* 4.1
Aspartate aminotransferase (/l) 28  13 30  20 29  13 31  14 39  70‡ 31
Cholesterol (mg/dl) 189  53 211  52 204  54 204  48 204  39† 202  50
*p  0.001, †p  0.05, and ‡p  0.01 for comparison across quintiles. Data are presented as the mean value  SD (continuous variables) or frequency (categorical variables).
BP  blood pressure; MCV  mean corpuscular volume; NYHA  New York Heart Association.
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rather than a linear or graded relationship. The results were
similar whether Hct was evaluated in quintiles, in deciles, or
continuously. The magnitude of the increased risk is strik-
ing, with a 52% higher risk of death in the lowest quintile of
Hct compared with the highest quintile. This increased risk
is more than twice the risk associated with diabetes, smok-
ing, a decade of age, or a 10% difference in EF in this
population.
Potential explanations. There are several possible expla-
nations for these findings. Although the associations per-
sisted after adjustment for a wide variety of demographic,
clinical, and laboratory characteristics, a lower Hct value
may be a marker for some other factor that increases
mortality among patients with severe HF. For example,
anemia may be a marker for poor renal function or volume
overload. However, there were only modest differences in
blood urea nitrogen and serum creatinine associated with
Hct, and no significant differences in NYHA functional
class, diuretic use, or serum sodium. Moreover, the higher
risk persisted after adjustment for these factors, suggesting
that baseline differences in these characteristics did not
entirely mediate the relationship between anemia and mor-
tality.
Anemia may also be a marker for higher circulating
cytokines and chemokines, which are associated with both
anemia of chronic disease and higher mortality in HF
(14–16). Lower Hct levels were associated with lower white
blood cell counts, suggesting possible generalized bone
marrow hypoproduction; decreased production may also
extend to other organs, as suggested by liver function
indexes. Systemic inflammation and immune activation in
HF may be related to bacterial endotoxin translocation
resulting from bowel wall edema and altered gut permeabil-
ity (17); interestingly, from our clinical experience, HF
patients with suspected bowel edema often show evidence of
poor iron absorption, which may further exacerbate anemia.
There are also plausible biologic mechanisms for a causal
relationship between anemia and mortality in HF. Myocar-
Figure 1. Kaplan-Meier survival according to quintiles of hematocrit. *p  0.004 for equality of survivor functions.
Table 2. Total Mortality According to Quintiles of Hematocrit
First Second Third Fourth Fifth
Hematocrit (%) 37.6 37.6–40.6 40.7–43.0 43.1–46.0 46.0
Deaths per 100 person-years 41 28 25 26 26
Unadjusted HR (95% CI) 1.56 (1.16–2.10) 1.07 (0.78–1.47) 0.97 (0.69–1.32) 1.00 (0.73–1.38) 1.0 (referent)
Adjusted HR* (95% CI) 1.52 (1.11–2.10) 1.18 (0.84–1.65) 1.10 (0.79–1.53) 1.12 (0.81–1.55) 1.0 (referent)
*Adjusted for age, gender, diabetes, smoking, heart failure etiology, ejection fraction, New York Heart Association functional class, systolic blood pressure, white blood cell count,
and serum creatinine.
CI  confidence interval; HR  hazard ratio.
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dial ischemia may result from a reduced oxygen-carrying
capacity combined with a low EF and increased wall stress.
Among elderly patients with acute MI, blood transfusion is
associated with lower mortality when the initial Hct is
33%, but not when the initial Hct is higher (18), consis-
tent with a relative threshold of ischemia risk. Another
plausible biologic mechanism is chronically increased myo-
cardial work and adrenergic stimulation due to a diminished
oxygen-carrying capacity of anemic blood, resulting in
progressive HF. This hypothesis is supported by the strong
inverse association between Hct and death due to progres-
sive HF, rather than sudden death or other deaths. The
resting cardiac output begins to increase with hemoglobin
10 g/dl ( Hct 30 to 33%) (19), and this threshold is
likely higher in the setting of abnormal states such as severe
HF. Anemia independently predicts the development of HF
among both renal failure patients and renal transplant
recipients, independent of ischemic heart disease (20,21).
Additionally, anemia is associated with elevated plasma
catecholamines and alpha2-receptor densities among renal
failure patients, proportional to the degree of anemia, and
correction of anemia with erythropoietin reduces plasma
noradrenaline and alpha2-receptor density (22). Correction
of anemia reduces the cardiac output among renal failure
patients (23,24), and improves the EF and reduces symp-
toms and hospitalizations among HF patients (10,11),
further supporting the hemodynamic significance of anemia.
Shape of risk. We observed a threshold of risk for total
mortality, due to a graded inverse relationship with pump
failure death and a U-shaped relationship with other causes
of death (largely sudden death). Among patients referred for
heart transplant evaluation, Hct was inversely associated
Figure 2. Mortality rates according to deciles of hematocrit (Hct). Compared with the reference group (tenth decile, Hct 48.3%), higher mortality was
only present in the first decile (Hct 35.4%), in which there was a 72% higher risk of death (hazard ratio 1.72, 95% confidence interval 1.13 to 2.62) after
adjustment for potential confounders (Table 2, footnote).
Table 3. Total Mortality According to Quintiles of Hematocrit Among Men and Women
First Second Third Fourth Fifth
Men (n) 173 172 176 167 171
Hematocrit (%) 38.2 38.2–41.3 41.4–43.7 43.8–46.8 46.8
Deaths per 100 person-years 45 34 25 24 27
Unadjusted HR (95% CI) 1.71 (1.23–2.38) 1.28 (0.91–1.81) 0.95 (0.66–1.36) 0.90 (0.62–1.30) 1.0 (referent)
Adjusted HR* (95% CI) 1.57 (1.09–2.25) 1.36 (0.95–0.96) 1.09 (0.75–1.59) 0.95 (0.65–1.40) 1.0 (referent)
Women (n) 55 55 54 54 53
Hematocrit (%) 36.8 36.8–38.7 38.8–40.9 41.0–43.7 43.7
Deaths per 100 person-years 36 21 15 30 23
Unadjusted HR (95% CI) 1.50 (0.80–2.83) 0.90 (0.44–1.82) 0.64 (0.31–1.34) 1.25 (0.65–2.40) 1.0 (referent)
Adjusted HR* (95% CI) 1.62 (0.83–3.14) 1.10 (0.53–2.30) 0.64 (0.30–1.35) 1.76 (0.88–3.50) 1.0 (referent)
*See Table 2 footnote.
Abbreviation as in Table 2.
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with total mortality, largely due to the risk of progressive
HF (9). The relationships with non-pump failure deaths did
not appear to be U-shaped (G. C. Fonarow, personal
communication, September 2002), as suggested by our
study. Further investigation is necessary to determine
whether there is a threshold of risk, a graded relationship, or
a U-shaped relationship between Hct and mortality in HF,
taking into consideration that this relationship may differ
depending on the cause of death, as suggested by our results.
Study strengths. Our analysis has several strengths. Pa-
tients were enrolled from multiple centers, rather than from
a single HF or transplant clinic, which increases the gener-
alizability. All patients were receiving similar background
medical therapy, including angiotensin-converting enzyme
inhibitors, diuretics, and digitalis. Demographic, clinical,
and laboratory characteristics were well characterized using
standardized techniques, increasing the capacity to adjust
for confounders. The predominant mortality end point was
death (98%), rather than transplantation (2%). Comprehen-
sive follow-up, review of events, and centralized adjudica-
tion minimized the potential for missed or misclassified
outcomes.
Study limitations. There are also potential limitations to
our findings. Hematocrit was assessed at baseline and may
have changed over time; such misclassification might cause
underestimation of the associations between Hct and mor-
tality. Also, although we adjusted for a wide variety of
participant characteristics, residual confounding due to un-
measured or incompletely measured factors cannot be ex-
cluded. These patients were participants in a randomized
clinical trial, so the results may not be generalizable to all
patients with severe HF. We did not have information on
levels of iron, erythropoietin, or cytokines and chemokines,
so we could not differentiate etiologies of anemia. As this
was a completed study and no further enrollment was
possible, we did not calculate the power a priori; post hoc
calculations showed 80% power to detect a 33% increase
in mortality risk across the quintiles of Hct.
Conclusions. Our findings indicate that anemia is a sig-
nificant independent risk factor for death among patients
with severe HF, particularly death due to progressive pump
failure. If this association is causal, normalization of Hct in
this population would be expected to reduce mortality by
approximately 33% based on the magnitude of risk observed
Table 4. Mortality by Different Causes According to Quintiles of Hematocrit
First Second Third Fourth Fifth
Pump failure death
Deaths per 100 person-years 19 14 10 10 6
Unadjusted HR (95% CI) 3.22 (1.85–5.61) 2.37 (1.34–4.19) 1.73 (0.96–3.15) 1.75 (0.97–3.17) 1.0 (referent)
Adjusted HR* (95% CI) 3.18 (1.77–5.72) 2.67 (1.48–4.84) 2.08 (1.13–3.83) 1.99 (1.09–3.64) 1.0 (referent)
Sudden death/other death†
Deaths per 100 person-years 22 14 15 16 20
Unadjusted HR (95% CI) 1.08 (0.75–1.56) 0.70 (0.46–1.04) 0.73 (0.50–1.08) 0.79 (0.54–1.15) 1.0 (referent)
Adjusted HR* (95% CI) 1.04 (0.70–1.55) 0.76 (0.49–1.16) 0.81 (0.54–1.22) 0.86 (0.58–1.22) 1.0 (referent)
*See Table 2 footnote. †Including nonfatal myocardial infarction and noncardiac deaths.
Abbreviations as in Table 2.
Figure 3. Mortality rates by cause of death, according to quintiles of hematocrit. Hematocrit was inversely associated with pump failure death (black bars)
(p for trend 0.001). In contrast, there was a suggestion of a U-shaped relationship with sudden deaths (white bars) and other deaths (striped bars) (see
text).
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in our study, or one less annual death for every eight patients
successfully treated. These results support the need for
further investigation of the etiologies, prevention, and
treatment of anemia in HF, including appropriately pow-
ered randomized clinical trials to determine whether pre-
vention or treatment of anemia reduces mortality in severe
HF.
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